Clinical Trials · NCT03937882
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- ReGenTree, LLC
- Enrollment
- 700
- Start date
- May 2019
- Locations
- 20 sites, United States
- Primary endpoint
- Corneal staining